TREACE MEDICAL CONCEPTS, INC.
جودة البيانات: 100%
TMCI
NASDAQ
Manufacturing
Measuring & Analyzing Instruments
KWD 1.81
▲
KWD 0.28
(18.30%)
القيمة السوقية: 98.15 M
السعر
KWD 1.52
القيمة السوقية
98.15 M
نطاق اليوم
—
نطاق 52 أسبوعًا
—
حجم التداول
—
فتح —
متوسط 50 يوم / 200 يوم
—
متوسط 50 يوم / 200 يوم
—
Quick Summary
النقاط الرئيسية
Revenue grew 22.51% annually over 5 years — strong growth
Negative free cash flow of -29.49 M
Revenue growth is decelerating — 1Y growth trails 5Y average by 20.92%
Capital efficient — spends only 6.36% of revenue on capex
النمو
Revenue Growth (5Y)
22.51%
أعلى من متوسط القطاع (1.82%)
Revenue (1Y)1.59%
Earnings (1Y)N/A
FCF Growth (3Y)N/A
الجودة
Return on Equity
-63.17%
أقل من متوسط القطاع (-54.01%)
ROIC-26.48%
Net Margin-27.74%
Op. Margin-25.46%
الأمان
Debt / Equity
0.62
أعلى من متوسط القطاع (0.30)
Current Ratio3.37
Interest Coverage-10.18
التقييم
PE (TTM|NTM)
-1.66 | -2.01
أقل من متوسط القطاع (-1.49)
P/B Ratio1.10
EV/EBITDAN/A
Dividend YieldN/A
تاريخ السعر
الاتجاهات المالية
مقارنة الأقران
مقابل وسيط قطاع Manufacturing (1385 نظير)
مقارنة الأقران
مقابل وسيط قطاع Manufacturing (1385 نظير)| المقياس | السهم | وسيط القطاع |
|---|---|---|
| P/E | -1.7 | -1.5 |
| P/B | 1.1 | 1.6 |
| ROE % | -63.2 | -54.0 |
| Net Margin % | -27.7 | -41.5 |
| Rev Growth 5Y % | 22.5 | 1.8 |
| D/E | 0.6 | 0.3 |
السعر المستهدف للمحللين
4 محللين
Hold
الحالي
KWD 1.81
المستهدف
KWD 4.25
KWD 2.00
KWD 4.00
KWD 7.00
التوقعات
مكرر الربحية المستقبلي
-2.01
ربحية السهم المستقبلية
-KWD 0.90
الإيرادات المقدّرة
222.80 M
تقديرات الأرباح
| الفترة | تقدير ربحية السهم | تقدير الإيرادات | المحللون |
|---|---|---|---|
| FY2027 |
-KWD 0.90
-KWD 0.90 – -KWD 0.90
|
222.80 M | 1 |
| FY2026 |
-KWD 0.91
-KWD 0.91 – -KWD 0.91
|
205.92 M | 1 |
| الفترة | تقدير ربحية السهم | تقدير الإيرادات | المحللون |
|---|---|---|---|
| 2026 Q2 |
-KWD 0.29
-KWD 0.29 – -KWD 0.29
|
44.23 M | 1 |
| 2026 Q1 |
-KWD 0.31
-KWD 0.31 – -KWD 0.31
|
46.27 M | 1 |
مفاجآت الأرباح
آخر 4 أرباع
| الربع | EPS المقدر | EPS الفعلي | المفاجأة |
|---|---|---|---|
| Q42025 | -KWD 0.14 | -KWD 0.08 | +44.1% |
| Q32025 | -KWD 0.27 | -KWD 0.22 | +18.2% |
| Q22025 | -KWD 0.29 | -KWD 0.26 | +9.8% |
| Q12025 | -KWD 0.30 | -KWD 0.25 | +18.3% |
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 1.59% | Revenue Growth (3Y) | 6.61% |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | 22.51% | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | 212.69 M | Net Income (TTM) | -59.00 M |
| ROE | -63.17% | ROA | -29.28% |
| Gross Margin | 79.81% | Operating Margin | -25.46% |
| Net Margin | -27.74% | Free Cash Flow (TTM) | -29.49 M |
| ROIC | -26.48% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | 0.62 | Current Ratio | 3.37 |
| Interest Coverage | -10.18 | Asset Turnover | 1.06 |
| Working Capital | 97.09 M | Tangible Book Value | 69.01 M |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | -1.66 | Forward P/E | -2.01 |
| P/B Ratio | 1.10 | P/S Ratio | 0.46 |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | 0.44 | Fwd Earnings Yield | N/A |
| FCF Yield | -30.04% | ||
| Market Cap | 98.15 M | Enterprise Value | 145.79 M |
| Per Share | |||
| EPS (Diluted TTM) | -0.93 | Revenue / Share | 3.29 |
| FCF / Share | -0.46 | OCF / Share | -0.25 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | 6.36% | FCF Conversion | 49.98% |
| SBC-Adj. FCF | -63.66 M | Growth Momentum | -20.92 |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 212.69 M | 209.36 M | 187.12 M | 141.84 M | 94.42 M |
| Net Income | -59.00 M | -55.74 M | -49.53 M | -42.82 M | -20.55 M |
| EPS (Diluted) | -0.93 | -0.90 | -0.81 | -0.77 | — |
| Gross Profit | 169.75 M | 168.26 M | 151.94 M | 114.32 M | 76.59 M |
| Operating Income | -54.15 M | -55.69 M | -51.43 M | -34.84 M | -16.51 M |
| EBITDA | — | — | — | — | — |
| R&D Expenses | 20.28 M | 20.59 M | 15.44 M | 13.58 M | 10.20 M |
| SG&A Expenses | — | — | — | — | — |
| D&A | 10.62 M | 8.42 M | 5.35 M | 2.13 M | 685,000.0 |
| Interest Expense | 5.32 M | 5.26 M | 5.17 M | 4.40 M | 4.06 M |
| Income Tax | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 190.58 M | 217.09 M | 251.91 M | 159.02 M | 140.82 M |
| Total Liabilities | 103.25 M | 104.20 M | 113.97 M | 98.50 M | 47.75 M |
| Shareholders' Equity | 87.33 M | 112.89 M | 137.94 M | 60.53 M | 93.07 M |
| Total Debt | 57.33 M | 53.31 M | 53.01 M | 52.71 M | 29.37 M |
| Cash & Equivalents | 10.71 M | 11.35 M | 12.98 M | 19.47 M | 105.83 M |
| Current Assets | 132.05 M | 161.40 M | 198.36 M | 133.40 M | 137.97 M |
| Current Liabilities | 30.64 M | 34.93 M | 45.03 M | 30.25 M | 18.21 M |
{"event":"ticker_viewed","properties":{"ticker":"TMCI","listing_kind":"stock","pathname":"/stocks/tmci","exchange":"NASDAQ","country":"US"}}